A selective EZH2 inhibitor that has activity against both wild-type and Y641F mutant EZH2 (IC50s = 15 and 13 nM, respectively); blocks cellular H3K27 methylation and activates PRC2-specific gene expression; decreases proliferation, cell cycle arrest, and apoptosis in diffused large B cell lymphoma cells carrying Y641 mutations